DUPIXENT®
(dupilumab) Injection
200mg · 300mg

INDICATION

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

DOSAGE AND ADMINISTRATION GUIDE

Not actual patients.

THE FIRST AND ONLY TREATMENT FOR EoE PATIENTS AS YOUNG AS 1 YEAR

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia and Psoriatic Arthritis: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Cases of new-onset psoriatic arthritis requiring systemic treatment have been reported with the use of DUPIXENT. Advise patients to report new-onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information and Instructions here.

HOW TO USE DUPIXENT

Weight-tiered dosage regimen[1]

1+ YEAR OF AGE

No loading dose

15 to <30 kg	Every **2 weeks**	**200 mg**[a] 1 pre-filled pen or syringe
30 to <40 kg	Every **2 weeks**	**300 mg**[b] 1 pre-filled pen or syringe
≥40 kg[c]	Every **week**	**300 mg**[b] 1 pre-filled pen or syringe

[a] 200 mg=1.14 mL solution.
[b] 300 mg=2 mL solution.
[c] The recommended dosage of 300 mg QW for pediatric subjects 1 to 11 years of age weighing ≥40 kg is based on modeled pharmacokinetic data to provide comparable exposures to the 300 mg QW dosage in adult and pediatric subjects 12 years of age and older weighing ≥40 kg with EoE.[1]

Administer at different injection sites[1]



- Administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
- The upper arm can also be used if a caregiver administers the injection
- Rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred

Injection by caregiver only
Self-injection or by caregiver

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥2%) in patients with EoE are injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.

OPTION TO ADMINISTER AT HOME OR IN OFFICE

Administration options[1]

PRE-FILLED PEN
(FOR AGES 2+ YEARS)

Available in 200 mg and 300 mg

PRE-FILLED SYRINGE
(FOR AGES 1+ YEAR)



Available in 200 mg and 300 mg

- DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider[1]
- A caregiver or patient 12 years of age and older may inject DUPIXENT using the pre-filled syringe or pre-filled pen[1]
  - In children 12 years of age and older, it is recommended that DUPIXENT be given by or under the supervision of an adult
  - In children 1 year to less than 12 years of age, weighing at least 15 kg, DUPIXENT should be given by a caregiver
- Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use[1]
- Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT[1]

MISSED DOSE INFORMATION

- If a weekly dose is missed, administer the dose as soon as possible, and start a new weekly schedule from the date of the last administered dose.[1]
- If an every other week dose is missed, administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.[1]

VIEW ADMINISTRATION INSTRUCTIONS

IMPORTANT SAFETY INFORMATION

USE IN SPECIFIC POPULATIONS (cont'd)

- **Pregnancy (cont'd):** Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information and Instructions here.

DUPIXENT®
(dupilumab) Injection
200mg · 300mg

HELP ENSURE YOUR ELIGIBLE PATIENTS CAN START AND STAY ON TRACK

DUPIXENT myway®

The DUPIXENT team provides eligible patients with support that supplements what your office offers

DUPIXENT MyWay support

Every enrolled patient is assigned a dedicated *DUPIXENT MyWay*® Case Manager who takes a patient-centric approach to providing tools, support resources, and education throughout the patient's treatment journey

COVERAGE SUPPORT

Assistance navigating the insurance process, including: conducting benefits investigations, providing prior authorization support,[a] and educating about the appeal process

PATIENT ACCESS SUPPORT

Financial support for eligible patients over the course of the treatment journey including copay card and quick-start programs

PATIENTS CAN ENROLL IN *DUPIXENT MyWay* BY CALLING 1-844-DUPIXEN(T) OR BY VISITING DUPIXENT.COM AND COMPLETING THE ENROLLMENT FORM

IMPORTANT SAFETY INFORMATION

USE IN SPECIFIC POPULATIONS (cont'd)

- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

[a] *DUPIXENT MyWay* can provide certain limited support.

[b] Subject to the program maximum per patient per calendar year. Approval is not guaranteed. **THIS IS NOT INSURANCE**. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

Reference: 1. DUPIXENT Prescribing Information.

Please see Important Safety Information throughout and accompanying full Prescribing Information and Instructions here.

sanofi | REGENERON®

DUPIXENT® (dupilumab) Injection
200mg · 300mg

US.DUP.25.04.0524
05/2025